Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Atezolizumab +1 More for Solid Tumors
Recruiting2 awardsPhase 1 & 2
New York, New York
This trial tests DRP-104, a new cancer drug, alone and with atezolizumab, an immune-boosting drug, in patients with advanced solid tumors, especially those with specific genetic mutations. DRP-104 aims to kill cancer cells directly, while atezolizumab helps the immune system fight the cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service